These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29512075)

  • 1. The Use of
    Ortner MM
    Methods Mol Biol; 2018; 1750():213-219. PubMed ID: 29512075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain fluorodeoxyglucose (FDG) PET in dementia.
    Kato T; Inui Y; Nakamura A; Ito K
    Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
    Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
    J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
    Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT.
    Tripathi M; Tripathi M; Damle N; Kushwaha S; Jaimini A; D'Souza MM; Sharma R; Saw S; Mondal A
    Neuroradiol J; 2014 Feb; 27(1):13-21. PubMed ID: 24571830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.
    Mosconi L; Tsui WH; Herholz K; Pupi A; Drzezga A; Lucignani G; Reiman EM; Holthoff V; Kalbe E; Sorbi S; Diehl-Schmid J; Perneczky R; Clerici F; Caselli R; Beuthien-Baumann B; Kurz A; Minoshima S; de Leon MJ
    J Nucl Med; 2008 Mar; 49(3):390-8. PubMed ID: 18287270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early differential diagnosis between Alzheimer's disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT.
    Chiba Y; Iseki E; Fujishiro H; Ota K; Kasanuki K; Suzuki M; Hirayasu Y; Arai H; Sato K
    Psychiatry Res Neuroimaging; 2016 Mar; 249():105-12. PubMed ID: 26857415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India.
    Mukku SSR; Sivakumar PT; Nagaraj C; Mangalore S; Harbishettar V; Varghese M
    Asian J Psychiatr; 2019 Aug; 44():99-105. PubMed ID: 31336358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
    Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Alzheimer's disease metabolic brain pattern in mild cognitive impairment.
    Meles SK; Pagani M; Arnaldi D; De Carli F; Dessi B; Morbelli S; Sambuceti G; Jonsson C; Leenders KL; Nobili F
    J Cereb Blood Flow Metab; 2017 Dec; 37(12):3643-3648. PubMed ID: 28929833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
    Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
    Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
    Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.